Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

@article{Nyholm2006PharmacokineticOI,
  title={Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.},
  author={Dag Nyholm},
  journal={Clinical pharmacokinetics},
  year={2006},
  volume={45 2},
  pages={
          109-36
        }
}
Pharmacotherapy for Parkinson's disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa and dopamine receptor agonists. The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses. The long-duration of response to levodopa, which is evident in early Parkinson's disease, diminishes and after a few years of treatment motor performance is closely correlated… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 56 CITATIONS

FILTER CITATIONS BY YEAR

2007
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

Similar Papers

Loading similar papers…